ID   WM852
AC   CVCL_6804
SY   WM-852; WM 852; WML 852; WC00065; EST84
DR   EFO; EFO_0022366
DR   cancercelllines; CVCL_6804
DR   Coriell; WC00065
DR   Cosmic; 886832
DR   Cosmic; 972282
DR   Cosmic; 1047657
DR   Cosmic; 1155275
DR   Cosmic; 1303079
DR   Cosmic; 2163811
DR   Cosmic; 2479249
DR   ESTDAB; ESTDAB-084
DR   GEO; GSM109044
DR   GEO; GSM156017
DR   GEO; GSM952601
DR   IARC_TP53; 1193
DR   IARC_TP53; 26084
DR   Progenetix; CVCL_6804
DR   Rockland; WM852-01-0001
DR   Wikidata; Q54994323
RX   PubMed=4053039;
RX   PubMed=8342600;
RX   PubMed=15592718;
RX   PubMed=16827748;
RX   PubMed=17260012;
RX   PubMed=19340423;
RX   PubMed=23851445;
WW   Info; Wistar; -; https://www.wistar.org/our-scientists/meenhard-herlyn
CC   Part of: Wistar Institute melanoma cell line collection.
CC   HLA typing: A*03:01,02:01; B*15:01:01:01,07:02; C*03:04,07:02; DPB1*04:01; DQB1*06:02,03:02; DRB1*04:01,15:01 (PubMed=15592718).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012).
CC   Sequence variation: Gene deletion; HGNC; HGNC:9588; PTEN; Zygosity=Hemizygous (Wistar).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; None_reported; -; Zygosity=- (Wistar).
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445; Wistar).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445).
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Variations; Array-based CGH.
CC   Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in Cellosaurus and May 2018. The major changes were: D18S51: 18->16, D5S818: 12,13->13, D8S1179: 12,13->13 and FGA: 21->21,26.
CC   Misspelling: VM852; Cosmic=2479249.
CC   Discontinued: Coriell; WC00065; probable.
CC   Derived from site: Metastatic; Abdomen, skin; UBERON=UBERON_0001416.
ST   Source(s): ESTDAB=ESTDAB-084; Wistar
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 11,12
ST   D16S539: 13,14
ST   D18S51: 16
ST   D19S433: 13,14
ST   D21S11: 30
ST   D2S1338: 16,17
ST   D3S1358: 15,18
ST   D5S818: 13
ST   D7S820: 8,10
ST   D8S1179: 13
ST   FGA: 21,26
ST   TH01: 6,7
ST   TPOX: 8
ST   vWA: 14,15 (Wistar)
ST   vWA: 15,17 (ESTDAB=ESTDAB-084)
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   63Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 14-08-25; Version: 36
//
RX   PubMed=19340423; DOI=10.1007/s00262-009-0701-z; PMCID=PMC11030131;
RA   Mendez, Rosa
RA   Aptsiauri, Natalia
RA   Del Campo, Ana
RA   Maleno, Isabel
RA   Cabrera, Teresa
RA   Ruiz-Cabello Osuna, Francisco
RA   Garrido, Federico
RA   Garcia-Lora, Angel
RT   "HLA and melanoma: multiple alterations in HLA class I and II
RT   expression in human melanoma cell lines from ESTDAB cell bank.";
RL   Cancer Immunol. Immunother. 58:1507-1515(2009).
//
RX   PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x;
RA   Hoek, Keith S.
RA   Schlegel, Natalie C.
RA   Brafford, Patricia
RA   Sucker, Antje
RA   Ugurel, Selma
RA   Kumar, Rajiv
RA   Weber, Barbara L.
RA   Nathanson, Katherine L.
RA   Phillips, Donald J.
RA   Herlyn, Meenhard
RA   Schadendorf, Dirk
RA   Dummer, Reinhard
RT   "Metastatic potential of melanomas defined by specific gene expression
RT   profiles with no BRAF signature.";
RL   Pigment Cell Res. 19:290-302(2006).
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5; PMCID=PMC11032966;
RA   Rodriguez, Teresa
RA   Mendez, Rosa
RA   Roberts, Chrissy H.
RA   Ruiz-Cabello Osuna, Francisco
RA   Dodi, I. Anthony
RA   Lopez-Nevot, Miguel Angel
RA   Paco, Laura
RA   Maleno, Isabel
RA   Marsh, Steven G.E.
RA   Pawelec, Graham
RA   Garrido, Federico
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=17260012; DOI=10.1038/sj.onc.1210252;
RA   Jonsson, Goran
RA   Dahl, Christina
RA   Staaf, Johan
RA   Sandberg, Troy
RA   Bendahl, Par-Ola
RA   Ringner, Markus
RA   Guldberg, Per
RA   Borg, Ake
RT   "Genomic profiling of malignant melanoma using tiling-resolution
RT   arrayCGH.";
RL   Oncogene 26:4738-4748(2007).
//
RX   PubMed=4053039;
RA   Herlyn, Meenhard
RA   Thurin, Jan
RA   Balaban-Malenbaum, Gloria Brady
RA   Bennicelli, Jeannette L.
RA   Herlyn, Dorothee
RA   Elder, David E.
RA   Bondi, Edward
RA   Guerry, DuPont 4th
RA   Nowell, Peter Carey
RA   Clark, Wallace H. Jr.
RA   Koprowski, Hilary
RT   "Characteristics of cultured human melanocytes isolated from different
RT   stages of tumor progression.";
RL   Cancer Res. 45:5670-5676(1985).
//
RX   PubMed=8342600; PMCID=PMC1887031;
RA   Juhasz, Istvan
RA   Albelda, Steven M.
RA   Elder, David E.
RA   Murphy, George Francis
RA   Adachi, Koji
RA   Herlyn, Dorothee
RA   Valyi-Nagy, Istvan T.
RA   Herlyn, Meenhard
RT   "Growth and invasion of human melanomas in human skin grafted to
RT   immunodeficient mice.";
RL   Am. J. Pathol. 143:528-537(1993).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl, Christina
RA   Christensen, Claus
RA   Jonsson, Goran
RA   Lorentzen, Anders
RA   Skjodt, Mette Louise
RA   Borg, Ake
RA   Pawelec, Graham
RA   Guldberg, Per
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//